Characterization of D-cyclin proteins in hematolymphoid neoplasms: Lack of specificity of cyclin-D2 and D3 expression in lymphoma subtypes

Modern Pathology

Volumn 23, Issue 3, 2010, Pages 420-433

  Metcalf, Ryan A ^a   Zhao, Shuchun ^a   Anderson, Matthew W ^a   Lu, Zhi Shun ^a   Galperin, Ilana ^a   Marinelli, Robert J ^a   Cherry, Athena M ^a   Lossos, Izidore S ^b   Natkunam, Yasodha ^a  

^a STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF MIAMI MILLER SCHOOL OF MEDICINE   (United States)

Author keywords

CCND2; CCND3; Cyclin D2; Cyclin D3; Diffuse large B cell lymphoma; Tissue microarray

Indexed keywords

CYCLIN D1; CYCLIN D2; CYCLIN D3; CYCLINE; PARAFFIN;

ACUTE GRANULOCYTIC LEUKEMIA; ARTICLE; CELL CYCLE REGULATION; CHROMOSOME TRANSLOCATION; CLASSICAL HODGKIN LYMPHOMA; FLUORESCENCE IN SITU HYBRIDIZATION; FOLLICULAR LYMPHOMA; HUMAN; HUMAN CELL; HUMAN TISSUE; LARGE CELL LYMPHOMA; LYMPHOBLASTOMA; LYMPHOMA; MAJOR CLINICAL STUDY; MANTLE CELL LYMPHOMA; MARGINAL ZONE LYMPHOMA; PATHOGENESIS; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; T CELL LYMPHOMA; TISSUE MICROARRAY;

EID: 77649272309     PISSN: 08933952     EISSN: 15300285     Source Type: Journal    
DOI: 10.1038/modpathol.2009.173     Document Type: Article

References (34)

1. Malumbres M, Barbacid M. Cell cycle, CDKs and cancer: a changing paradigm. Nat Rev Cancer 2009;9:153-166.
2. Malumbres M, Sotillo R, Santamaria D, et al. Mammalian cells cycle without the D-type cyclin-dependent kinases Cdk4 and Cdk6. Cell 2004;118:493-504.
3. Sherr CJ. G1 phase progression: cycling on cue. Cell 1994;79:551-555.
4. Suzuki R, Kuroda H, Komatsu H, et al. Selective usage of D-type cyclins in lymphoid malignancies. Leukemia 1999;13:1335-1342.
5. Rosenberg CL, Wong E, Petty EM, et al. PRAD1, a candidate BCL1 oncogene: mapping and expression in centrocytic lymphoma. Proc Natl Acad Sci USA 1991;88:9638-9642.
6. Swerdlow SH, Campo E, Harris NL, et al. WHO Classification of Tumours of Haematopoietic and Lymphoid Tissues. IARC: Lyon, 2008.
7. Fu K, Weisenburger DD, Greiner TC, et al. Cyclin D1-negative mantle cell lymphoma: a clinicopathologic study based on gene expression profiling. Blood 2005;106:4315-4321.
8. Gesk S, Klapper W, Martin-Subero JI, et al. A chromosomal translocation in cyclin D1-negative/cyclin D2-positive mantle cell lymphoma fuses the CCND2 gene to the IGK locus. Blood 2006;108:1109-1110.
9. Herens C, Lambert F, Quintanilla-Martinez L, et al. Cyclin D1-negative mantle cell lymphoma with cryptic t(12;14)(p13;q32) and cyclin D2 overexpression. Blood 2008;111:1745-1746.
10. Wlodarska I, Dierickx D, Vanhentenrijk V, et al. Translocations targeting CCND2, CCND3, and MYCN do occur in t(11;14)-negative mantle cell lymphomas. Blood 2008;111:5683-5690.
11. Lossos IS, Czerwinski DK, Alizadeh AA, et al. Prediction of survival in diffuse large-B-cell lymphoma based on the expression of six genes. N Engl J Med 2004;350:1828-1837.
12. Malumbres R, Chen J, Tibshirani R, et al. Paraffin-based 6-gene model predicts outcome in diffuse large B-cell lymphoma patients treated with R-CHOP. Blood 2008;111:5509-5514.
13. Hans CP, Weisenburger DD, Greiner TC, et al. Expression of PKC-beta or cyclin D2 predicts for inferior survival in diffuse large B-cell lymphoma. Mod Pathol 2005;18:1377-1384.
14. Moller MB, Nielsen O, Pedersen NT. Cyclin D3 expression in non-Hodgkin lymphoma. Correlation with other cell cycle regulators and clinical features. Am J Clin Pathol 2001;115:404-412.
15. Natkunam Y, Lossos IS, Taidi B, et al. Expression of the human germinal center-associated lymphoma (HGAL) protein, a new marker of germinal center B-cell derivation. Blood 2005;105:3979-3986.
16. Natkunam Y, Warnke RA, Montgomery K, et al. Analysis of MUM1/IRF4 protein expression using tissue microarrays and immunohistochemistry. Mod Pathol 2001;14:686-694.
17. Marinelli RJ, Montgomery K, Liu CL, et al. The stanford tissue microarray database. Nucleic Acids Res 2008;36:D871-D877.
18. Natkunam Y, Zhao S, Mason DY, et al. The oncoprotein LMO2 is expressed in normal germinal-center B cells and in human B-cell lymphomas. Blood 2007;109: 1636-1642.
19. Su TT, Rawlings DJ. Transitional B lymphocyte subsets operate as distinct checkpoints in murine splenic B cell development. J Immunol 2002;168:2101-2110.
20. Solvason N, Wu WW, Parry D, et al. Cyclin D2 is essential for BCR-mediated proliferation and CD5 B cell development. Int Immunol 2000;12:631-638.
21. Jena N, Deng M, Sicinska E, et al. Critical role for cyclin D2 in BCR/ABL-induced proliferation of hematopoietic cells. Cancer Res 2002;62:535-541.
22. Alizadeh AA, Eisen MB, Davis RE, et al. Distinct types of diffuse large B-cell lymphoma identified by gene expression profiling. Nature 2000;403: 503-511.
23. Klier M, Anastasov N, Hermann A, et al. Specific lentiviral shRNA-mediated knockdown of cyclin D1 in mantle cell lymphoma has minimal effects on cell survival and reveals a regulatory circuit with cyclin D2. Leukemia 2008;22:2097-2105.
24. Chiles TC. Regulation and function of cyclin D2 in B lymphocyte subsets. J Immunol 2004;173:2901-2907.
25. Ehinger M, Linderoth J, Christensson B, et al. A subset of CD5\ diffuse large B-cell lymphomas expresses nuclear cyclin D1 with aberrations at the CCND1 locus. Am J Clin Pathol 2008;129:630-638.
26. Rodriguez-Justo M, Huang Y, Ye H, et al. Cyclin D1-positive diffuse large B-cell lymphoma. Histopathol-ogy 2008;52:900-903.
27. Wang SA, Wang L, Hochberg EP, et al. Low histologic grade follicular lymphoma with high proliferation index: morphologic and clinical features. Am J Surg Pathol 2005;29:1490-1496.
28. Thompson MA, Stumph J, Henrickson SE, et al. Differential gene expression in anaplastic lymphoma kinase-positive and anaplastic lymphoma kinase-ne-gative anaplastic large cell lymphomas. Hum Pathol 2005;36:494-504.
29. Natkunam Y, Farinha P, Hsi ED, et al. LMO2 protein expression predicts survival in patients with diffuse large B-cell lymphoma treated with anthracycline-based chemotherapy with and without rituximab. J Clin Oncol 2008;26:447-454.
30. Teramoto N, Pokrovskaja K, Szekely L, et al. Expression of cyclin D2 and D3 in lymphoid lesions. Int J Cancer 1999;81:543-550.
31. Sehn LH, Donaldson J, Chhanabhai M, et al. Introduction of combined CHOP plus rituximab therapy dramatically improved outcome of diffuse large B-cell lymphoma in British Columbia. J Clin Oncol 2005;23:5027-5033.
32. Coiffier B, Lepage E, Briere J, et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002;346:235-242.
33. Habermann TM, Weller EA, Morrison VA, et al. Rituximab-CHOP versus CHOP alone or with maintenance rituximab in older patients with diffuse large B-cell lymphoma. J Clin Oncol 2006;24:3121-3127.
34. Pfreundschuh M, Trumper L, Osterborg A, et al. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group. Lancet Oncol 2006; 7:379-391.